Vaccinia Virus (Lister Strain) Rabbit Polyclonal Antibody

CAT#: BP1076F

Vaccinia Virus (Lister Strain) rabbit polyclonal antibody, FITC

Specifications

Product Data

• Applications: ELISA, IF, IHC
• Recommended Dilution: ELISA
  Immunofluorescence: Direct FA staining of target antigens in a permissive tissue culture system.
  A starting range of 1/10-1/50 is suggested.
  Immunohistochemistry (Proteinase K digestion is recommended with formalin-fixed paraffin-embedded sections).
• Reactivities: Vaccinia virus
• Host: Rabbit
• Clonality: Polyclonal
• Immunogen: Lister Strain (mixture of virions and infected cell polypeptides).
• Specificity: Recognizes purified virions.
  Does not cross-react with Parainfluenza (1-3), RSV, adenovirus, Influenza A & B or HSV-1.
  Does not react with uninfected cells.
  Reactive with Lister, Wyeth, New York City and MVA strains of Vaccinia.
• Formulation: 0.01M PBS, pH 7.2
  Label: FITC
  State: Liquid purified IgG fraction
  Stabilizer: 10 mg/ml BSA
  Preservative: 0.09% Sodium Azide
  Label: Covalently coupled with high purity Isomer I of Fluorescein Isothiocyanate Care is taken to ensure complete removal of any free fluorescein from the final product
• Concentration: lot specific
• Purification: Affinity Chromatography
• Conjugation: FITC
• Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
  This product is photosensitive and should be protected from light.
  Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.
• Background: Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As Vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During Vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize Vaccinia virus infection and enable identification other viral and cellular proteins which participate in the Vaccinia virus entry process.